Physician profile
Jacinda Chan
NPI 1588265854
$30,689.32
in general payments reported to CMS, 2019-2025
30 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,514 · 2023: $4,115 · 2024: $5,703 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,375 · Consulting Fee: $5,182 · Education: $682 · Travel and Lodging: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,660.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,375.00 |
| Consulting Fee | $5,182.00 |
| Education | $682.12 |
| Travel and Lodging | $274.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $10,865.41 | 2023-2025 | Nemluvio, Aklief |
| Incyte Corporation | $3,576.41 | 2022-2025 | Opzelura, Opzelura |
| Abbvie INC. | $2,711.62 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $2,084.50 | 2022-2025 | Absorica Ld, Winlevi, Ilumya |
| Ucb, INC. | $1,944.06 | 2023-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $1,693.57 | 2023-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $1,445.02 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $1,120.51 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $819.13 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $737.83 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $537.68 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Dermavant Sciences, INC. | $518.13 | 2023-2024 | Vtama |
| Pfizer INC. | $500.96 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $499.73 | 2023-2025 | |
| Leo Pharma INC. | $292.86 | 2023-2025 | Anzupgo, Adbry |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $219.70 | 2024-2025 | Ycanth |
| Biocon Biologics INC | $175.82 | 2025 | Yesintek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.69 | 2022-2023 | Spevigo |
| Janssen Scientific Affairs, LLC | $143.69 | 2022 | |
| Botanix Sb INC | $127.73 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $84.87 | 2023-2025 | Jublia, Cabtreo |
| Amgen INC. | $84.85 | 2023-2025 | Otezla |
| Genentech USA, INC. | $72.73 | 2022 | |
| Epi Health, LLC | $38.13 | 2022 | |
| Glaxosmithkline, LLC. | $34.57 | 2024 | Bexsero |
| Kyowa Kirin, INC. | $31.09 | 2023-2025 | Poteligeo |
| Organon LLC | $24.84 | 2025 | Vtama |
| Blueprint Medicines Corporation | $22.26 | 2025 | Ayvakit |
| Lnhc, INC | $14.94 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacinda Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.